You are looking at doing the clinical trials for the IN105 oral insulin drug overseas because of a delay in India. How big a concern is this
It is a big concern because for all of us, who are trying to do drug innovation in India, it will be difficult to take everything outside India. You can see Quintiles has shut down its phase 1 unit in the country. All the big contract research organisations are folding up in India and MNCs are saying we dont want to do trials in India. It is not a good thing.
Apart from the IN105 trials, does this impact Clinigenes clinical services business
Clinigene has always been a small part of our research services business. Over time, it has differentiated its model. It is not focussing much on conducting big phase clinical trials, so because of that it is not affected. We are merging it with Syngene, so it is not really affecting us in that sense. But if you look at it from a longer term point of view, if clinical trials were a very big sector in India, then Clinigene could have benefitted from it.
What has been driving the growth in the research services arm
Basically, Syngene is surging ahead if you compare it to any other research services company in India because we have high-end capability. We completely went away from the commoditised, fee-for-service model. I think we see ourselves being the market leader in Asia. Today we are No.2, WuXi (Chinas WuXi AppTec) is still No.1. But in the near future, we expect to overtake WuXi once our CRAMS (contract research and manufacturing services) business becomes more mature. Today, we are just supplying clinical quantities of material but when we start supplying commercial quantities, then our business can be much larger. Thats what separates us and them because they supply commercial-scale innovative products.
How will you step up capability
We will be doing a lot of capacity expansion for Syngene. There are various aspects, I mean, if we have to set up a manufacturing-scale plant, then that is something which we will look at. Over the next five years we are looking at about $100 million of capital expenditure for Syngene.
Whats been the uptake for Biocons new psoriasis drug Alzumab and the plan for taking it to other markets
Im actually surprised because our forecast was very conservative and the uptake we have seen in the first month is much beyond our expectations. We want to go to the big markets, the US and Europe.